| Li, Yuanyuan |
NCT03574324: TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC |
|
|
| Recruiting | 3 | 266 | RoW | TPF+CCRT, Experimental group, CCRT+PF, Control group | Guiyang Medical University | Locally Advanced Nasopharyngeal Carcinoma | 05/23 | 05/23 | | |
NCT06198764: A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection |
|
|
| Recruiting | 3 | 80 | RoW | Colistimethate sodium for injection, Meropenem for Injection, Coly Mycin M Injectable Product | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Mental Health Issue | 03/26 | 03/26 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
public, NCT06162286: A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP |
|
|
| Recruiting | 3 | 100 | RoW | Omadacycline, Moxifloxacin | Zai Lab (Hong Kong), Ltd. | Community-acquired Bacterial Pneumonia | 01/25 | 11/25 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT05039606: Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma |
|
|
| Not yet recruiting | 2 | 164 | RoW | Nedaplatin, Cisplatin | Guiyang Medical University | Head and Neck Squamous Carcinoma | 09/26 | 09/26 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
NCT04518774: Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial |
|
|
| Recruiting | 1 | 8 | RoW | Ex-vivo expanded allogeneic γδT cells | Beijing 302 Hospital, Chinese Academy of Medical Sciences, Beijing GD Initiative Cell Therapy Technology Co., Ltd. | Hepatocellular Carcinoma | 06/21 | 08/21 | | |
ICU, NCT06514781: The Application of Different Sedation Protocols in Patients With Severe Pneumonia |
|
|
| Recruiting | N/A | 600 | RoW | | Xiangya Hospital of Central South University | Severe Pneumonia | 12/24 | 12/24 | | |
NCT05665010: Precise Stratification of Genetic Risk of Ovarian Function Impairment |
|
|
| Recruiting | N/A | 1000 | RoW | Genetic susceptibility | Tongji Hospital | Premature Ovarian Insufficiency, Diminished Ovarian Reserve, Early Menopause | 10/23 | 10/24 | | |
